Delving into the Latest Updates on DWJ-1248 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

DWJ1248

Target-

Action-

Mechanism-

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication-

Inactive Indication

COVID-19

Originator Organization

Daewoong Pharmaceutical Co., Ltd.

Active Organization-

Inactive Organization

Daewoong Pharmaceutical Co., Ltd.

License Organization-

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Login to view timeline

A Phase 1, Open label, Dose escalation and Dose expansion study of SCO-120 in HR +ve HER2-ve advanced/ metastatic breast cancer (MBC) patients to evalaute the safety, tolerability and prelimnary efficacy. Initial part with dose escalation is to determine the MTD and RP2D, and PK and PD characterisation. RP2D will be further evalauted for prelimnary efficacy in MBC patients with tretament failure on Aromatase Inhibitor/Fulvestrant/CDK4-6 inhibitors with or with out ESR1 mutation.

Start Date20 May 2022

Sponsor / Collaborator

Sun Pharma Advanced Research Co. Ltd.

NCT04721535

/ TerminatedPhase 3

A Randomized Double-blinded Controlled Clinical Trial of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2

To evaluate the prevention of SARS-COV-2 infection after administration of DWJ1248 in person who contact from COVID-19 confirmed patient compared to the placebo.

Start Date07 Jun 2021

Sponsor / Collaborator

Daewoong Pharmaceutical Co., Ltd.

NCT04782505

/ CompletedPhase 1

A Open-label, Single-dose, Phase 1 Study to Compare and Evaluate the Safety and Pharmacokinetics According to the Dose of Camostat Mesylate in Healthy Volunteers

Safety and pharmacokinetics evaluation study according to the dose of camostat mesylate in healthy volunteers

Start Date12 Mar 2021

Sponsor / Collaborator

Daewoong Pharmaceutical Co., Ltd.

100 Clinical Results associated with DWJ-1248

Login to view more data

100 Translational Medicine associated with DWJ-1248

Login to view more data

100 Patents (Medical) associated with DWJ-1248

Login to view more data

1

Literatures (Medical) associated with DWJ-1248

24 Jan 2023·Antimicrobial agents and chemotherapy

A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19

Article

Author: Han, Jumi ; Oh, Myoung-don ; Ra, Seung Won ; Kim, Yeonjae ; Kang, Beo Deul ; Lee, Ji Yeon ; Kang, Seung ji ; Choi, Jae-phil ; Shin, Yun Chul ; Choi, Jongwon ; Park, Hyun-jin ; Park, MiHee ; Lee, Boyoung ; Jung, Minji ; Kim, Sung-Han ; Han, Se Hee ; Kim, Junghee ; Yoon, Aeri ; Kim, Hyun ah ; Kim, YuKyung ; Koh, Jong Hoon ; Jeon, Seng-Ho ; Kim, Jin Yong ; Kim, JooHyun ; Kim, Choon Kwan ; Kim, Hyoung jun ; Kim, Yeon-Sook ; Peck, Kyong Ran ; Heo, Jung Yeon ; Kim, Ji Won ; Park, Chul Hee ; Lee, Chung Hoon ; Yu, Shi Nae ; Park, SuJung

Although several antiviral agents have become available for coronavirus disease 2019 (COVID-19) treatment, oral drugs are still limited. Camostat mesylate, an orally bioavailable serine protease inhibitor, has been used to treat chronic pancreatitis in South Korea, and it has an in vitro inhibitory potential against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

100 Deals associated with DWJ-1248

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 3	South Korea	Daewoong Pharmaceutical Co., Ltd.	02 Feb 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04521296 (Pubmed)	Phase 2	COVID-19	432	Camostat Mesylate (DWJ1248)	yitzniszqm(zlybngikfr) = wuudmkuhky brufzofscs (ouenbkbsec ) View more	Negative	14 Dec 2022
				Placebo	yitzniszqm(zlybngikfr) = uixhqsuimh brufzofscs (ouenbkbsec ) View more